Trials / Completed
CompletedNCT04009057
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Multi-center, Israeli, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 143 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA \< 50 copies/mL, at 12 months after initiating or switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | B/F/TAF | B/F/TAF administered in accordance with the approved product monograph |
Timeline
- Start date
- 2019-07-09
- Primary completion
- 2022-03-21
- Completion
- 2022-03-21
- First posted
- 2019-07-05
- Last updated
- 2022-05-03
Locations
5 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT04009057. Inclusion in this directory is not an endorsement.